Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Jiayi Lin¹*, Jinmei Jin¹*, Yiwen Shen¹*, Lijun Zhang¹, Gang Gong¹, Huiting Bian¹, Hongzhuan Chen¹, Dale G. Nagle³, Ye Wu¹**, Weidong Zhang¹,²**, and Xin Luan¹**

1. Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
2. School of Pharmacy, Second Military Medical University, Shanghai, 201203, China
3. Department of Biomolecular Sciences and Research of Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, 38677-1848, USA

*These authors contributed equally to this work.

Corresponding authors: Dr. Ye Wu, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; orcid.org/0000-0003-4974-0774; Email: wuye@shutcm.edu.cn. Prof. Weidong Zhang, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; School of Pharmacy, Second Military Medical University, Shanghai, 201203, China; orcid.org/0000-0002-7384-2490; Email: dzhangy@hotmail.com. Prof. Xin Luan, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; orcid.org/0000-0003-3674-256X; Email: luanxin@shutcm.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2021.05.12; Accepted: 2021.07.03; Published: 2021.07.13

Abstract

Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as “undruggable” before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.

Key words: targeted protein degradation (TPD), extracellular and membrane proteins, LYTAC, AbTAC

Introduction

Remarkable advances in human genetic studies have revealed a broad spectrum of protein targets that associate with disease progression [1, 2]. The classical small molecule inhibitor paradigm has been pursued worldwide through large-scale screening and structure-based optimization by academic and industry groups. Nevertheless, traditional drug discovery approaches usually require accessible binding sites and measurable biochemical index of target proteins, thus, only a small portion of human proteome is pharmacologically druggable [3]. The majority of disease-causing proteins, including scaffolding proteins, transcription factors, and other non-enzymatic proteins are rendered as undruggable targets for a long time [4, 5].

Targeted protein degradation (TPD) has emerged to be a powerful tool to handle these undruggable targets and exhibits significant therapeutic benefit over standard small-molecule inhibition strategy [6]. A full degradation of disease-causing proteins provides the chance for ablation of target protein as well as all of its associated biological functions. It has been demonstrated that small molecules can induce protein degradation at the post-translational level, which occur with estrogen receptor alpha (ERα), inhibitor of apoptosis protein...
Overview of the novel degrader technologies

Over the last two decades, the breakthrough progress in TPD technologies not only provides useful tools for biological discovery, but also offers viable therapeutic candidates in clinic. We herein summarize the novel technologies with different mechanisms, as shown in Figure 1, and discuss their potential applications and limitations.

Intracellular proteins degradation

PROTAC

A PROTAC molecule consists of a targeting warhead for intracellular POI and an E3 ligase ligand for recruitment of E3, which are connected by a flexible linker [26]. The formation of a POI-PROTAC-E3 ternary complex induces ubiquitination of the POI and subsequent its degradation cascade by the 26S proteasome [27]. The PROTAC concept provides a powerful strategy for targeting those “undruggable” proteins that lack an active site for an inhibitor to bind or is not addressable by an inhibitor [28]. Of note, event-driven degradation induced by PROTAC is catalytic and sub-stoichiometric due to its multiple cycles of degradation mechanism [29,30]. Currently, a variety of PROTAC molecules have been designed and validated in preclinical settings and two oral PROTACs ARV-110 targeting AR (NCT03888612) and ARV-471 for ER (NCT04072952) have shown promising prospects in phase I clinical trials with good efficacy and safety profile [19,31,32]. Despite the promising clinical data, PROTACs have certain limitations to target those “undruggable” proteins with large shallow surfaces as well as extracellular proteins [10,33-35]. Small molecules and peptides are currently the main targeting warheads used by PROTAC design. However, those ligands have corresponding limitations. Among them, small molecules heavily rely on the binding pockets of POI [36], while peptide ligand application is limited to poor cellular membrane penetration and stability in vivo [37]. Moreover, PROTAC has faced challenges such as further expansion of human E3 ligases, reducing off-target toxicity, and the optimal linker-length determination, which have hindered its development. For example, because only a handful of E3 ubiquitin ligases are available, the current application of PROTAC is restricted. Similar to PROTAC, other UPS-based modalities using limited E3, like molecular glue, dTAG, and Trim-Away, are under restrictions.
**AUTAC and ATTEC**

In addition to the extensively utilized UPS in current TPD approaches, novel techniques such as AUTAC and ATTEC have been developed to modulate and control protein levels by harnessing the autophagy/lysosome pathway (reviewed in [38]), which offer a glimpse into future possibilities [11,12,39].

An AUTAC molecule consists of a small molecular binder of target protein and a guanine derivative as a degradation tag to trigger K63 polyubiquitination (different from the K48 polyubiquitination triggered by PROTACs) [11]. Ubiquitinated POIs are recognized by autophagy receptors such as p62/SQSTM1 and are linked to phagophores through the LC3-interacting region [40-42]. Despite the unique advantages of AUTAC for its specific and broad degradation scope, the underlying mechanisms of selective autophagy and its effects on the overall cellular proteins remain unclear and require further investigation.

Similar to AUTAC based on autophagy-lysosome system, ATTEC is a linker compound that tethers the POI to the autophagosome by interacting with both POI and LC3 proteins [12]. Owing to the advantages of its small size, ATTEC manipulates the protein levels more effectively. Meanwhile, it also reminds us that a largely unexplored area of compounds regulating therapeutically relevant proteins or other cytoplasmic substrates needs to be further exploited and clarified. These degraders all provide orthogonality and optimization for TPD platforms.

**Extracellular protein degradation**

Despite the promising prospect of TPD strategy, non-cytosolic proteins lied beyond the scope of TPD for a long time, which limited their further application. Encouragingly, the novel technologies, LYTAC and AbTAC, have emerged to broaden the spectrum of protein targets.

**LYTAC**

LYTAC is a novel technology that targets extracellular and/or membrane protein to induce
degradation by harnessing the endosome/lysosome pathway. It is a bifunctional conjugate that simultaneously binds the extracellular domain of a target and a cell-surface lysosome-targeting receptor (LTR) to form a ternary complex, leading to protein internalization via clathrin-mediated endocytosis [43]. After being engulfed, the complex successively passes through early endosome (EE) and late endosome (LE) where a low pH enables the complex to be dissociated [44]. Subsequently, POI proceeds to lysosome to be degraded, while LTR is recycled into cell membrane via recycling endosome (RE). Degradation mechanism of LYTAC is shown in Figure 2. Notably, compared to POI inhibition, LYTAC directly exerts degradation effect on protein, and therefore avoids the potential activation of other downstream pathways that may be caused by inhibitors [21]. Moreover, this degradation strategy prevents molecular compensation and cellular adaptation due to their higher depletion efficiency compared with genetic techniques like CRISPR-Cas9 [45].

**AbTAC**

Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different epitopes or antigens [46]. AbTAC is a fully recombinant bispecific immunoglobulins G (IgG) that can recruit transmembrane E3 ligases ring finger 43 (RNF43) [47] and cell-surface proteins simultaneously, inducing RNF43-AbTAC-protein complexes internalization and subsequent lysosomal degradation of POI [22], as shown in Figure 2. However, its mechanism of action is mainly remained elusive. Particularly, it remains unknown whether RNF43 ubiquitinates the intracellular regions of POI to induce endocytosis. Meanwhile, it needs to clarify what proteins are required for the AbTAC system and whether the RNF43-dependent degradation manner leads to other changes in cellular functions. Although there is no large cellular perturbation in whole-cell proteomics, the cell safety of AbTAC requires further proof [48]. In addition, when screening AbTAC for optimal degradation efficiency, we should also take the RNF43 cell specificity and endocytosis kinetics into account.

**Figure 2.** The schematic diagram of LYTAC and AbTAC. (A) M6Pn-LYTAC targets extracellular or membrane protein and is recognized by lysosome shuttling receptor Cl-M6PR at the cell surface, to form ternary complex, while GalNAc-LYTAC binds target protein and liver cell-surface ASGPR simultaneously. The resulting complex is engulfed by the cell membrane, endocytosed into endosomes, and degraded in lysosomes. (B) AbTAC binds to RNF43 and cell-surface proteins simultaneously, inducing RNF43-AbTAC-protein complexes internalization and lysosomal degradation. Figure created with BioRender.com.
To fully understand the discussed techniques and choose the appropriate one for the problem at hand, we compare the advantages and disadvantages of intracellular protein degradation strategies and the two extracellular protein degradation approaches (LYTAC and AbTAC), as shown in Table 1.

### Table 1. Advantages and disadvantages of five TPD technologies

| POIs                      | Techs  | Advantages                                                                                                           | Disadvantages                                                                 |
|---------------------------|--------|----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Intracellular proteins    | PROTAC | Clear mechanisms of action [49]; event-driven action [50]; catalytic degradation activity [51]; Stable degradation   | Limitation to cytosolic domain of proteins [36]; In a proteasome-dependent manner [45]; Poor cellular penetration needs to be solved [36] |
|                           | AUTAC  | Targeting organelles and intracellular proteins; selective autophagy [11,39]; Selective degradation [12]; Drug-like property [12] | Degradation mechanisms need further investigation [11,39]                     |
| Extracellular and membrane-bound proteins | LYTAC  | Targeting extracellular and membrane-bound proteins [21]; high selectivity in POIs and cell types [23,24]            | Poor tissue permeability [21]; Complex synthesis of LTR ligands M6Pn [21]; Possible immune response in vivo [52]; Lack of studies |
|                           | AbTAC  | Targeting membrane proteins; high bispecificity [22]                                                                 | High cost; Potential immunogenicity [53]; Unclear endocytosis mechanism [22] |

**LYTAC**

LYTAC is designed with one end binding to the POI and the other end recognized by LTR. The incorporation of a ligand for efficient drug delivery via a LTR has been widely explored [54]. Based on the structure of two substrates and the certain degradation mechanism, LYTAC has been rationally designed and synthesized, as shown in Figure 3.

**LRT-binding ligands**

**PolyM6Pn**

Cation-independent mannose-6-phosphate receptor (CI-M6PR), one member of cell-surface LTR families, can enclose hydrolases or other cargoes in endosomes, and subsequently deliver those proteins into lysosomes for depletion [55]. Based on the structure of CI-M6PR, studies have demonstrated that CI-M6PR can bind with mannose-6-phosphate (M6P) glycoproteins [56]. So far, M6P derivatives have been utilized in enzyme replacement therapies for lysosomal diseases or in neoplastic drug targeting usage [55]. In order to increase affinity, stability, and avoid cytotoxicity, multiple M6P analogues were designed and tested, and an appropriate ligand M6Pn glycopolypeptide was obtained. Additionally, factors targeting extracellular protein degradation is still in its infancy. In this part, we mainly summarize the design principles, recent progress, and current synthesis strategies of LYTAC and AbTAC, providing theoretical basis for the future application. By focusing on the successive conceptual and technical innovations in this field, we hope to encourage and inspire further efforts to optimize current techniques and create new TPD methods.
like length, chemical modification or side-chains should be further studied to achieve optimal CI-M6PR agonism [57].

M6Pn glycopolypeptides synthesis strategy starts with the conversion of mannose pentaacetate to M6Pn-NCA in 13 steps and ends with copolymerization of M6Pn-NCA to acquire poly(M6Pn) polypeptides [21]. However, as a ubiquitous receptor, the expression levels of CI-M6PR in various cell types may impact LYTAC-mediated degradation efficiency [21], or result in potential off-target effects. Moreover, some studies indicated that CI-M6PRs are overexpressed in specific cancer types (such as breast cancer) [58], and play a role in regulating cancer cell growth and motility [59]. However, whether this regulation effect is disrupted under the action of LYTAC is still unknown.

Tri-GalNAc

Unlike CI-M6PR, Asialoglycoprotein receptor (ASGPR) is a LTR which is highly expressed in hepatocytes [60]. Due to the ligand specificity and the ability of supporting multiple rounds of uptake [61], ASGPR has enormous potentials for liver cell specific degradation of proteins. On the basis of structure studies, it is clear that glycoproteins bearing N-acetylgalactosamine (GalNAc) or galactose (Gal) ligands can be recognized by ASGPR and internalized via clathrin-mediated endocytosis [62]. Indeed, GalNAc has already been applied as therapeutic nucleic acid agents in preclinical or clinical settings [63,64]. Studies also revealed that triantennary GalNAc (tri-GalNAc) ligands engage ASGPR with higher affinity compared to GalNAc [65,66]. Tri-GalNAc ligands are synthesized from peracetylated GalNAc to tri-GalNAc-DBCO in 8 steps, and then are conjugated to azides on non-specifically labeled antibodies [23]. Tang’s group directly used the commercially available Tri-GalNAc-COOH. After being converted to Tri-GalNAc-NHS (N-hydroxysuccinimide) ester, Tri-GalNAc ligands are conjugated with the lysine residues on the antibody [24]. Compared to M6Pn, selectively delivering undesired proteins to liver by tri-GalNAc ligands is much safer than ubiquitously delivery of POI to various types of cells [24]. We compare the advantages and disadvantages of polyM6Pn and tri-GalNAc in Table 2.

POI-binding ligands

The degradation ability of LYTAC also relies on the affinity between POI and its ligand. For targeting the significant disease-associative proteins, there are three choices for POI ligands, including antibodies, small molecules, and peptides [21,23-25]. Although having specific affinity with POI, antibodies with high molecular weight have lower tissue permeability than small molecules in several cases [68]. Take it further, the large molecular LYTAC labeled with an antibody needs to be miniaturized [52]. With the development of structure biology and virtual screening, small molecular targeting warheads possessing high affinity are selected [69]. Considering their inability to target “undruggable” proteins with large shallow surface, researchers have drawn their attentions towards specific binding peptides, which have advantages of lower production cost and amenability to chemical synthesis [70]. Compared to small molecules, peptides possess greater potential in structural modification by point mutation or truncation [34,71,72]. Generally, based on the crystal structure of endogenous complex of POI and binding protein, the key interacting residues can be analyzed to design the peptide targeting warheads [73]. To fully understand those POI ligands, we compared the advantages and disadvantages between them as shown in Table 3.

Table 2. Advantages and disadvantages of polyM6Pn and tri-GalNAc

| Advantage | Disadvantage |
|-----------|--------------|
| PolyM6Pn  | Complex inhomogeneity of structure [68]; complicated synthesis process [21] |
| Tri-GalNAc | Limitation on liver cells [23,24]; cell type-specific degradation [23,24] |

Table 3. Advantages and disadvantages of POI ligands

| Antigen | Antibodies | Small molecules | Peptides |
|---------|------------|-----------------|----------|
| Advantage | Specific affinity with POIs [74]; high affinity [59]; overexpression in specific cancer cells [58] | High stability and tissue permeability [21]; limited penetrability [36] | Low cost; easy to synthesise [61] |
| Disadvantage | High cost; low stability and tissue permeability [21]; potential immunogenicity [52] | Inability to target “undruggable proteins” [25] | Low stability; limited penetrability [36] |

Construction strategy: Click reaction chemistry

Chemically, a LYTAC molecule can be assembled via azide-alkyne cycloaddition (click chemistry) between a TLR ligand and a POI ligand. For example, following modular design and synthesis, a POI ligand labeling with azide group is conjugated with a TLR ligand with alknylation via copper-free strain-promoted click reaction, in turn, it also works that a POI ligand labeled with DBCO (dibenzocyclooctyne) or BCN can conjugate to an azide-labeled TLR ligand. After the conjugation reaction, the product is interrogated by native gel electrophoresis [21,23].
Theranostics 2021, Vol. 11, Issue 17

**AbTAC**

A single-pass E3 ligase: RNF43

As previously described, the AbTAC acts by assembling separately expressed half IgGs to form a bispecific IgG for degrading cell-surface proteins via RNF43 [22], which comprises a structured ectodomain, a transmembrane region, and an intracellular RING domain [46]. It was documented that RNF43 is widely expressed in a variety of cancer cells, such as MDA-MB-231, HCC827, and T24, etc., which provides generalizability for the degradation of RNF43-driven AbTAC [22]. In addition to that, RNF43 can negatively regulate the Wnt signaling pathway by ubiquitinating the Frizzled receptor, causing its endocytosis and degradation [76], which may open up possibilities to degrade the cell-surface POIs via endocytosis.

**Construction strategy: Knobs-into-holes (KIHs) technology**

The production of antibodies binding to RNF43 and POI begins with the phage display technique [77]. After multi-round selection strategies, clones with high affinities were identified by sequencing and assessing the on-cell binding ability [22]. Knobs-into-holes (KIHs) technology can prevent light chain mismatch pairing of half IgGs of anti-RNF43 and anti-POI, by creating either a “knob” or a “hole” in each heavy chain to promote heterodimerization [78]. The composition of AbTAC and its generation strategy are shown in Figure 4.

**Future Perspectives**

**Optimization of LYTAC and AbTAC**

**LYTAC**

CI-M6PR is highly expressed in fetal and neonatal tissues but it decreases postnaturally; however, it is overexpressed in some pathological conditions, such as fibrosis and some cancerous diseases [79-81]. For example, CI-M6PR is induced in a number of human carcinoma cells, such as breast cancer, pancreatic cancer, gastric cancer, melanoma, and prostate cancer [80]. Therefore, M6Pn-LYTAC is regarded as a more promising strategy for tumor therapy compared to GalNAc-LYTAC. Nevertheless, the construction of CI-M6PR-binding ligand, M6Pn glycopolypeptides, lacks precise manipulation, leading to the heterogeneity of products [21,57]. It is adverse for the subsequent study on structure optimization and structure-activity relationship. For instance, LYTACs with various glycopolypeptide length was observed only minor differences in uptake efficiency, suggesting that there should be a shortest M6Pn length to achieve high degradation efficiency. More important, smaller molecular size means lower immunogenicity [21]. Further, it was demonstrated that the projection topology of the saccharide units is of crucial importance for an efficient cell penetration mediated by CI-M6PR [59]. The spatial arrangement of glycopolypeptide needs to be further investigated.

**Figure 4.** Generation of bispecific IgG AbTAC. The recombinant antibody for RNF43 and POI was generated using phage display. These two IgGs are assembled to form an AbTAC utilizing the knobs-into-holes technology. Figure created with BioRender.com.
AbTAC

AbTAC represents a novel archetype to LYTAC with the ability to deplete cell-surface proteins. Despite its great promise in protein degradation, it is unclear how AbTAC recruit membrane-bound E3 ligases to induce cell-surface POI degradation via lysosome pathway. Only when the detailed regulation process is elucidated, could we make good use of this degradation pathway better. Moreover, a potential problem is whether there is appropriate distance between half IgGs for binding of membrane-bound E3 ligase and POIs at the same time. In this case, we envision that a bifunctional peptide with two warhead and a flexible linker can be used to target transmembrane E3 ligase and POIs simultaneously. We can also utilize phage display to rapidly generate targeting peptide for membrane-bound E3 ligases with high affinity and high specificity [82]. Meanwhile, there are so many existing tool peptides for disease related membrane proteins like PD-L1 [83], CD47 [84] and VEGFR [85]. Intermediate linker between two peptides is chosen according to actual situation, resulting in a “peptide version” AbTAC. We hope that accessible molecule will inspire the advancement of extracellular proteins degradation as a novel class of drug candidates.

Potential cell-surface lysosome targeting proteins

Currently, the number of E3 ubiquitin ligase ligands used in PROTAC technology is limited, which restricts their subsequent application and development. Also, it was verified that the loss of core components of E3 ligases leads to resistance to PROTACs [86]. Therefore, rather than overusing the same lysosome shuttling receptors, we do need to exploit new lysosome targeting proteins. For example, CD22 recycling receptor specifically expressing on B-cells [87] or mannose receptors (MR, CD206) presenting on tumor-associated macrophages (TAMs) surface [88,89] may be may be good choices for cell-specific degradation. Similarly, ZNRF3, another cell surface E3 ligase, provides a potential opportunity for the development of AbTACs [47]. In addition to cell surface receptors, intracellular lysosomal receptors, such as the lysosomal integral membrane protein (LIMP-2) and sortilin [90], might provide us with some enlightenments for targeting cytosolic proteins via lysosome system.

New possibilities for clinic

LYTAC gives failed drugs another chance

LYTAC provides possibilities to change protein ligands into degraders. TPD strategy possesses kinetic advantages by binding to any “nook” or “cranny” on POIs with low dose [91,92]. Generally, ligands that bind to the desired targets but were set aside because they could not adequately block protein function may be possible to be permitted as warheads of LYTAC. On the other hand, many preclinical or clinical ‘occupancy-driven’ molecules that have clear affinity with POI but not have gained FDA-approval due to their side effects can also be the warheads of LYTACs.

Multi-headed LYTAC and AbTAC-drug conjugates

Drug resistance and relapse are two major obstacles in cancer treatment [93], which can be avoided by rational polytherapy to target distinct pathogenetic mechanisms [94]. Recently, a series of PROTACs (MT-802, SJF620, and L18I) have been reported that they can overcome the resistance to ibrutinib induced by BTK mutations [95]. Based on this fact, we hypothesized that the “star molecule” multi-headed LYTACs might be able to overcome resistance with high efficiency and low toxicity [96,97].

Antibody-drug conjugates (ADC) are monoclonal antibodies conjugated to cytotoxic agents by environment-responsive linkers, which enable traditional drugs to have high tumor specificity and potency [98]. Five ADCs have since achieved FDA approval and more than 40 are now in or nearing clinical trials [99,100]. Here, we speculate the possibility of forming an AbTAC-drug conjugate (ATDC) as a multi-target agent. Ideally, after rational design of AbTAC linked to a drug, ATDC is able to degrade membrane protein to block the upstream signal, and further be internalized rapidly to deliver the linked drug intracellularly. Additionally, it requires that the linker is stable in blood circulation, and further be internalized rapidly to deliver the linked drug intracellularly. Additionally, it requires that the linker is stable in blood circulation yet is readily cleavable at the target site. Future studies in MOA of AbTAC will possibly help to further develop AbTAC as a mature technology and discover effective multi-target agent.

Delivery nanosystem

Because LYTACs are macromolecules different from those of traditional protein-targeting small molecules, their aqueous solubility, drug delivery, and pharmacokinetics, and adverse reaction remain elusive. We estimate that the universal expression of cell-surface LTR and the instability of LYTACs may cause off-target effect and short drug half-life. Nanoparticles (NPs) have emerged as a powerful drug-delivery tool to enhance the specificity of drug actions, while reducing the systemic side effects [101]. For instance, The ARV-loaded NPs successfully improved the solubility, permeability, pharmacokinetics, and delivery of ARV, showing promising
anticancer activity. Moreover, surface modification of PLGA NPs with PEG can impart high serum stability and prolonged half-life to PROTAC [102,103]. To ensure PROTAC delivery at the desired site in the required proportions, Ocaña and colleagues established PROTAC-loading NPs conjugated with antibody trastuzumab (selectively binds to the extracellular domain of HER2) to improve target selectivity, and cytotoxic efficacy for the treatment of breast cancer [104]. According to these cases of PROTAC-loading NPs, we propose that LYTAC-loading NPs might enable prolonged circulation and targeted delivery through elaborate design. Besides, “passively” targeted NPs are the most extensively explored strategy targeting cancer, by utilizing the enhanced permeability and retention (EPR) effect [105]. Moreover, stimuli-responsive NPs based on extrinsic stimuli have reached clinical trials and received approval [106]. We believe that it is promising to explore the feasibility and application of LYTACs delivery nanosystem.

Conclusion

Nowadays, TPD has been recognized as a game-changing strategy by inducing the degradation of the ‘undruggable’ targets and PROTACs have broken the classical Lipinski’s rule of five [107]. However, the substrates of PROTACs are limited to intracellular proteins through proteasomal clearance. LYTACs and AbTACs have emerged as potential therapeutics by taking advantage of the lysosome system to degrade disease-relevant extracellular and membrane proteins. Notably, there are also challenges in this nascent field, such as limited studies on length of linker, structure optimization, ternary complex equilibria, and pharmacokinetics. The critical next step is to develop them into mature technologies through interdisciplinary collaboration, which can provide more solutions. For example, synthetic procedure of M6Pn glycoproteins is interminable and inefficient. To increase efficiency, we can develop CI-M6PR-binding oligopeptides to replace the long M6P chain or simplify synthetic steps in chemistry, or search for other TLRs from a biological standpoint. Furthermore, the screening of LYTACs generally depends on measuring protein levels through western blot assay or mass spectroscopy, which is time-consuming. Development of computational tools that provide high-throughput methods to design and screen LYTACs may be a trend [108]. Moreover, the concept of degradation strategy offers possibilities to degrade RNA genome, further establishing more therapeutic tools at the level of genetic degradation [109,110].

In conclusion, by focusing on TPD strategies towards extracellular and membrane proteins, we hope to provide readers with a resource to help navigate in this booming field, and inspire further efforts to create new degradation modalities.

Abbreviations

TPD: targeted protein degradation; PROTAC: PROteolysis TArgeting Chimera; POI: protein of interest; LYTAC: LYsosome-TArgeting Chimaera; AbTAC: Antibody-based PROTAC; Erα: estrogen receptor alpha; AR: androgen receptor; AUTAC: autophagy-targeting chimera; ATTEC: autophagosome-tethering compounds; dTAG: degradation tag; Cl-M6PR: cation-independent mannose-6-phosphate receptor; ASGPR: asialoglycoprotein receptor; ApoE4: apolipoprotein E4; EGFR: epidermal growth factor receptor; PD-L1: programmed death-ligand 1; UPS: ubiquitin-proteasome system; LTR: lysosome-targeting receptor; EE: early endosome; LE: late endosome; RE: recycling endosome; bsAbs: Bispecific antibodies; IgG: immunoglobulins G; RNF43: cell-surface transmembrane E3 ubiquitin ligase ring finger 43; ZNRF3: cell-surface transmembrane E3 ubiquitin ligase zinc and ring finger 3; VEGFR: vascular endothelial growth factor receptor; M6P: mannose-6-phosphate; GalNAc: glycoproteins bearing N-acetylgalactosamine; Gal: galactose; tri-GalNAc: triantennary glycoproteins bearing N-acetylgalactosamine; DBCO: dibenzocyclooctyne; BCN: cyclopropane cyclooctyne; KIHs: Knobs-into-holes; MR: mannose receptor; TAM: tumor-associated macrophage; LIMP: lysosomal integral membrane protein; ADC: Antibody-drug conjugate; ATDC: AbTAC-drug conjugate; MOA: mode of action; NPs: Nanoparticles.

Acknowledgements

Funding

This work was supported by funds from the National Natural Science Foundation of China (No.81903654), Shanghai Science and Technology Innovation Action Plan (21SI1902800), Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning (QD2018035), Shanghai Sailing Program (19YF1449400), State Key Laboratory of Innovative Natural Medicine and TCM Injections (No. QFSKL2020017 and QFSKL2020019), National Key Research and Development Program of China (2017YFC1700200), Graduate Innovation Training research project of the Shanghai University of Traditional Chinese Medicine (No. Y2021003).
Competing Interests

The authors have declared that no competing interest exists.

References

1. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei J, et al. Identification and characterization of essential genes in the human genome. Science. 2015; 350: 1096-101.

2. Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017; 170: 564-76.

3. Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the ‘undruggable’ cancers. Nat Rev Cancer. 2017; 17: 502-8.

4. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018; 17: 353-77.

5. Roskoski RJ. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019; 144: 19-50.

6. Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019; 18: 949-63.

7. Fukui S, Nakai Y, Matsumoto Y, Kagebayashi Y, Samma S. Investigation of incidence and risk factors of subcutaneous granulomas induced by injection of leuprorelin acetate. Hinyokika Kiyo. 2015; 61: 55-9.

8. Preissler-Mashek MT, Solodin N, Stark BL, Tyriver MK, Alarid ET. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017; 171: 1692-706.

9. Takahashi D, Arimoto H. Targeting selective autophagy by AUTACs: a new drug target. Curr Opin Pharmacol. 2020; 58: 632-8.

10. Li Z, Zhu C, Ding Y, Fei Y, Lu B. ATTEC: a potential new approach to ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015; 22: 575-63.

11. Moreau K, Coen M, Zhang AX, Patil F, Castaldi MP, Dahl G, et al. Proteolysis-targeting chimeras in drug development: A safety perspective. Br J Pharmacol. 2020; 177: 1709-18.

12. An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. Ebiomedicine. 2020; 56: 553-62.

13. Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018; 14: 163-70.

14. Takahashi D, Arimoto H. Targeting selective autophagy by AUTACs: a novel strategy for targeted protein ubiquitination and degradation. Nat Rev Drug Discov. 2018; 17: 13: 2149-75.

15. Nabet B, Roberts JM, Buckley DL, Pauljk J, Dastjerdi S, Yang A, et al. The PROTAC system for immediate and target-specific protein degradation. Nat Chem Biol. 2018; 14: 431-41.

16. Nabet B, Ferguson FM, Seong B, Kuljanin M, Leggett AL, Mohardt ML, et al. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nat Commun. 2020; 11: 4687.

17. Clift D, So C, McEwan WA, James LC, Schuh M. Acute and rapid degradation of endogenous proteins by Trim-Away. Nat Protoc. 2018; 13: 2149-75.

18. Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, et al. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017; 171: 1692-706.

19. Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the ‘undruggable’ cancers. Nat Rev Cancer. 2017; 17: 502-8.

20. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015; 347: 1260419.

21. Moreau K, Coen M, Zhang AX, Patil F, Castaldi MP, Dahl G, et al. Proteolysis-targeting chimeras in drug development: A safety perspective. Br J Pharmacol. 2020; 177: 1709-18.

22. An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. Ebiomedicine. 2020; 56: 553-62.
Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, et al. Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther. 2017; 25: 71-81.

Gary-Bobo M, Nirdé P, Jeanne A, Morère A, Garcia M. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem. 2007; 14: 2945-53.

Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, et al. GalNAc-siRNA conjugate. Mol Ther. 2017; 25: 71-81.

Höbert E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep. 2006; 26: 7-17.

Ali L, Simon M, El CK, Aguesseau-Kondrotas J, Godefroy A, Nguyen C, et al. Topological requirements for CI-M6PR-mediated cell uptake. Bioconjug Chem. 2019; 30: 2533-8.

Spies M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry-U. 1990; 29: 10009-18.

Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci. 2002; 7: d717-25.

Schwartz AL, Fridovich SE, Lodish HF. Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J Biol Chem. 1982; 257: 4230-7.

Zhang M, Wang T, Sigua LH, Qi J. Peptide-based PROTAC: The predator of pathological proteins. Cell Chem Biol. 2020; 27: 637-9.

Lee YC, Townsend RR, Hardy MR, Lönngren J, Arnarp J, Haraldsson M, et al. Determination of the upper size limit for uptake and degradation of peptides and antibodies. Anal Bioanal Chem. 2019; 411: 3757-94.

Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the bet bromodomain protein BRD4. Acs Chem Biol. 2015; 10: 1770-7.

Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, et al. Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy. Cancer Immunol Res. 2018; 6: 178-88.

Jiang Y, Deng Q, Zhao H, Xie M, Chen L, Yin F, et al. Development of stabilized peptide-based PROTACs against estrogen receptor α. Acs Chem Biol. 2018; 13: 628-35.

Yin F, Wang J, Sigua LH, QJ. Peptide-based PROTAC: The predator of pathological proteins. Cell Chem Biol. 2020; 27: 637-9.

Eskandari S, Guerin T, Toth I, Stephenson RJ. Recent advances in self-assembled peptides: Implications for targeted drug delivery and vaccine engineering. Adv Drug Deliv Rev. 2017; 110-111: 169-87.

Tas JM, Meslin L, Fasqual G, Targ S, Jacobsen JT, Mano YM, et al. Visualizing antibody affinity maturation in germlen cells. Science. 2016; 351: 1048-54.

Pelayo-Miguel G, Glas A, Koch O, Grossmann TN. Structure-based design of inhibitors of protein-protein interactions: Mimicking peptide binding epitopes. Angew Chem Int Ed. 2015; 54: 8996-927.

Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific Nanoformulation of PROteolysis TArgeting Chimera targeting the PD -1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. J Immunother Cancer. 2020; 8: e000905.

Romalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Obe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020; 382: 41-50.

Chatterjee N, Bivona TG. Polytherapy and targeted cancer drug resistance. Trends Cancer. 2019; 5: 170-82.

Buhimschi AD, Armstrong HA, Touré M, Jaime-Figueroa S, Chen TL, Lehman AM, et al. Targeting the C481S ibrutinib-resistance mutation in Bruton's tyrosine kinase using PROTAC-mediated degradation. Biochemistry-U. 2018; 57: 3564-75.

Gao J, Wang F, Wang S, Liu L, Liu K, Ye E, et al. Hyperthermia-triggered on-demand biomimetic nanocarriers for synergistic photothermal and chemotherapy. Adv Sci. 2020; 7: 1903642.

Wang Y, Han L, Liu F, Yang F, Jiang X, Sun H, et al. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. Colloids Surf B Bio interfaces. 2020; 188: 110795.

Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019; 394: 793-804.

Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016; 17: e254-62.

Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. Mabs-Austin. 2014; 6: 34-45.

Fam SY, Choe CF, Yong CY, Ho KL, Mariatulqabtiah AR, Tan WS. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials. 2020; 10: 787.

Minko T. Nanoformulation of BRD4-Degrading PROTAC: Improving druggability to target the ‘undruggable’ MYC in pancreatic cancer. Trends Pharmacol Sci. 2020; 41: 684-6.

Cimats FJ, Zebisch M, Xu Y, Tran C, Heibeck TH, Wang WD, Yang J, et al. Production of bispecific antibodies in ‘knobs-into-holes’ using a cell-free expression system. Mabs-Austin. 2015; 7: 231-42.

Ye Z, Cheng K, Guntaka RV, Mahato RI. Targeted delivery of a triplex-forming oligonucleotide to hepatocellular stellate cells. Biochemistry-U. 2005; 44: 4466-76.

Vaillant O, El CK, Warther D, Brevet D, Maynadier M, Bouffard E, et al. Mannose-6-phosphate receptor: a target for theranostics of prostate cancer. Angew Chem Int Ed Engl. 2015; 54: 9592-6.
106. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60.
107. Chagas CM, Moss S, Alisaraie L. Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski’s Rule of Five. Int J Pharm. 2018; 549: 133-49.
108. Douglass EJ, Miller CJ, Sparer G, Shapiro H, Spiegel DA. A comprehensive mathematical model for three-body binding equilibria. J Am Chem Soc. 2013; 135: 6692-9.
109. Liu X, Haniff HS, Childs-Disney JL, Shuster A, Aikawa H, Adibekian A, et al. Targeted degradation of the oncogenic microRNA 17-92 cluster by structure-targeting ligands. J Am Chem Soc. 2020; 142: 6970-82.
110. Haniff HS, Tong Y, Liu X, Chen JL, Suresh BM, Andrews RJ, et al. Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders. ACS Cent Sci. 2020; 6: 1713-21.

Author Biographies

Xin Luan, Ph.D., Professor, earned his Bachelor's degree (2011) in Pharmaceutics from China Pharmaceutical University. He received his PhD degree (2016) in Pharmacology at Shanghai Jiao Tong University, under the supervision of Prof. Hongzhuan Chen and Prof. Chao Fang. Then he joined the research group of Prof. Duxin Sun at the University of Michigan as a postdoctoral fellow. In late 2018, he started his independent career at Shanghai University of Traditional Chinese Medicine. His current research focus on the discovery, modification, and targeted delivery of anti-cancer compounds from Traditional Chinese Medicine.

Weidong Zhang, Ph.D., Professor, is currently a professor of the Shanghai University of Traditional Chinese Medicine and Second Military Medical University. He obtained his Bachelor’s degree and Master’s degree from Second Military Medical University in 1988 and 1991, respectively. He received his PhD in Natural Product Chemistry in 1998 from Shanghai Institute of Pharmaceutical Industry with Professor Hui-Ting Li. His research focuses on total synthesis, biological function, structural modification, structure-activity relationship of structurally complex and bioactive natural products.

Ye Wu, Ph.D., obtained his Bachelor’s degree (2013) and Master’s degree (2017) in Medicinal Chemistry at Chengdu Medical College. He received his PhD in Shanghai University of Traditional Chinese Medicine in 2021 with the supervision of Prof. Wei-Dong Zhang and Prof. Xin Luan. In the same year, he became a Postdoctoral Research Fellow with Prof. Hong-Zhuhan Chen and Prof. Xin Luan. His research focuses on the conformational constraint and targeted delivery of peptide drugs.

Jiayi Lin obtained her Bachelor's degree from the School of Chinese Medicine, Southern Medical University in 2020. She is currently studying for a master's degree at Shanghai University of Traditional Chinese Medicine, under the supervision of Prof. Xin Luan. Her research is centered on development of LYTAC and related oncotherapy.

Jinmei Jin obtained her Master’s degree (2019) in institute of Chinese Materia Medica at Shanghai University of Traditional Chinese Medicine. She is currently a Ph.D. student under the supervision of Prof. Hong-Zhuhan Chen. Her current research is centered on the synthesis of peptide PROTAC and related oncotherapy.
Yiwen Shen received her Bachelor's degree in Zhejiang Agriculture and Forestry University in 2019 and now studies in Shanghai University of Traditional Chinese Medicine under the supervision of Prof. Wei-Dong Zhang. Her current research is focused on oncology drug discovery.